BioWorld

May 2, 2005

View Archived Issues

Amylin Scores Again: FDA Clears Byetta In Diabetes

FDA approvals are becoming routine for Amylin Pharmaceuticals Inc., which just received the agency's blessing for the second time in less than two months. (BioWorld Today) Read More

Advanced Life Sciences IPO: $86.25M To Boost Antibiotic

Read More

Lower IPO Valuations Quashing Early VC Biotechnology Funding

Read More

Ikaria Aiming To 'Buy Time' Via Reversible Hibernation

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More